SLC5A2 and bacterial urinary tract infection: In an observational Uitrakul et al. [90] study carried out in real clinical practice among patients with type 2 diabetes mellitus, it was revealed that the overall incidence rate of UTI was 33.49% in the SGLT2 inhibitor treated group vs. 11.72% in the group of patients without treatment with gliflozins.